Chronic renal allograft dysfunction: A role for mycophenolate mofetil? [1]

Transplantation

Volumn 69, Issue 8, 2000, Pages 1749-1750

  Pascual, M ^a   Williams, W W ^a   Cosimi, A B ^a   Delmonico, F L ^a   Farrell, M L ^a   Tolkoff Rubin, N ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; CHRONIC DISEASE; CLINICAL ARTICLE; DOSE CALCULATION; DRUG EFFICACY; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYALINE DEGENERATION; KIDNEY ALLOGRAFT; KIDNEY FUNCTION; KIDNEY TUBULE DISORDER; LETTER; MALE; PRIORITY JOURNAL;

EID: 0034720064     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200004270-00042     Document Type: Letter

References (8)

1. A novel approach to the treatment chronic allograft nephropathy
2. Chronic renal allograft dysfunction: No response to mycephenolate mofetil
3. Rethinking chronic allograft nephropathy: The concept of accelerated senescence
4. Chronic rejection and chronic cyclosporin toxicity in renal allografts
5. 1 mRNA: A correlate of interstitial fibrosis and chronic allograft nephropathy
6. Mycophenolate Mofetil in renal allograft recipients
7. Mycophenolate mofetil and reduction in cyclosporine dosage for chronic renal allograft dysfunction
8. Pathologic classification of chronic allograft nephropathy: Pathogenic and prognostic implications